Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer ConsortiumMiguel García-Pardo, Geoffrey Liu, Matthew B. Schabath et al.|Journal of Thoracic Oncology|2022Cited by 26
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Cell Reports Medicine|2025Cited by 12
<scp>DRD1</scp> suppresses cell proliferation and reduces <scp>EGFR</scp> activation and <i>PD‐L1</i> expression in <scp>NSCLC</scp>Christopher E. Grant, Bríd M. Ryan|Molecular Oncology|2024Cited by 9
Accounting for <i>EGFR</i> Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium DataSabine Schmid, Ping Yang, Mei Jiang et al.|Cancer Epidemiology Biomarkers & Prevention|2022Cited by 2
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignanciesRuth Plummer, Nagy Habib, Mikael H. Sodergren et al.|Regular and Young Investigator Award Abstracts|2022Cited by 1